Chinese Herbal Medicine Displays Potential Anti-Cancer Efficacy on Metastatic Prostate Cancer Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Sep 11

PMID 31500366

Citations 8

Authors

Wen-Chin Huang

Meng-Shiun Chang

Shih-Yin Huang

Ching-Ju Tsai

Pin-Hung Kuo

Han-Wen Chang

Sheng-Teng Huang

Chao-Lin Kuo

Shou-Lun Lee

Ming-Ching Kao

Affiliations

Soon will be listed here.

Abstract

Resistance to the current therapies is the main clinical challenge in the treatment of lethal metastatic prostate cancer (mPCa). Developing novel therapeutic approaches with effective regimes and minimal side effects for this fatal disease remain a priority in prostate cancer study. In the present study, we demonstrated that a traditional Chinese medicine, quality-assured ethanol extract (GTEE), significantly suppressed cell growth and metastatic capability and caused cell cycle arrest through decreasing expression of cyclins in mPCa cells, PC-3 and DU145 cells. GTEE also induced caspase-dependent apoptosis in mPCa cells. We further showed the potent therapeutic efficacy of GTEE by inhibiting subcutaneous PC-3 tumor growth in a xenograft model. The in vitro and in vivo efficacies on mPCa cells were due to blockade of the PI3K/Akt and MAPK/ERK signaling pathways associated with cancer cell growth, survival and apoptosis. These preclinical data provide the molecular basis for a new potential therapeutic approach toward the treatment of lethal prostate cancer progression.

Citing Articles

Phytochemical synergies in BK002: advanced molecular docking insights for targeted prostate cancer therapy.

Park M, Choi J, Maharub Hossain Fahim M, Asevedo E, Nurkolis F, Ribeiro R Front Pharmacol. 2025; 16:1504618.

PMID: 40034825 PMC: 11872924. DOI: 10.3389/fphar.2025.1504618.

Chinese herbal medicines for prostate cancer therapy: From experimental research to clinical practice.

Kong F, Wang C, Zhang J, Wang X, Sun B, Xiao X Chin Herb Med. 2023; 15(4):485-495.

PMID: 38094009 PMC: 10715895. DOI: 10.1016/j.chmed.2023.05.003.

BK002 Induces miR-192-5p-Mediated Apoptosis in Castration-Resistant Prostate Cancer Cells Modulation of PI3K/CHOP.

Park M, Park H, Rahman M, Kim J, Park S, Cho Y Front Oncol. 2022; 12:791365.

PMID: 35321434 PMC: 8936126. DOI: 10.3389/fonc.2022.791365.

Bioactive Compounds of Inhibited Methicillin-Resistant Growth by Affecting Their Cell Membrane Permeability and Integrity.

Chan Y, Chong K Molecules. 2022; 27(3).

PMID: 35164103 PMC: 8840476. DOI: 10.3390/molecules27030838.

Genome of Species Provides Insights Into the Evolution, Conifers Substrate Utilization, and Terpene Synthesis for .

Jiang N, Hu S, Peng B, Li Z, Yuan X, Xiao S Front Microbiol. 2021; 12:724451.

PMID: 34603250 PMC: 8481371. DOI: 10.3389/fmicb.2021.724451.

References

Kuok Q, Yeh C, Su B, Hsu P, Ni H, Liu M . The triterpenoids of Ganoderma tsugae prevent stress-induced myocardial injury in mice. Mol Nutr Food Res. 2013; 57(10):1892-6. DOI: 10.1002/mnfr.201200704. View

Bishop K, Kao C, Xu Y, Glucina M, Paterson R, Ferguson L . From 2000years of Ganoderma lucidum to recent developments in nutraceuticals. Phytochemistry. 2015; 114:56-65. DOI: 10.1016/j.phytochem.2015.02.015. View

Li X, Chen Y, Hu P, Huang W . Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol Cancer Ther. 2014; 13(4):855-66. PMC: 4084917. DOI: 10.1158/1535-7163.MCT-13-0797. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Boudadi K, Antonarakis E . Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. Clin Med Insights Oncol. 2016; 10(Suppl 1):1-9. PMC: 4798019. DOI: 10.4137/CMO.S34534. View

Hsu S, Ou C, Li J, Chuang T, Kuo H, Liu J . Ganoderma tsugae extracts inhibit colorectal cancer cell growth via G(2)/M cell cycle arrest. J Ethnopharmacol. 2008; 120(3):394-401. DOI: 10.1016/j.jep.2008.09.025. View

Shukla S, MacLennan G, Hartman D, Fu P, Resnick M, Gupta S . Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer. 2007; 121(7):1424-32. DOI: 10.1002/ijc.22862. View

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View

Li X, Wu J, Chung L, Huang W . Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations. Oncotarget. 2015; 6(38):41018-32. PMC: 4747386. DOI: 10.18632/oncotarget.5879. View

10.

Mostaghel E, Page S, Lin D, Fazli L, Coleman I, True L . Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007; 67(10):5033-41. DOI: 10.1158/0008-5472.CAN-06-3332. View

11.

Yu Y, Kuo H, Hsieh H, Li J, Hsu W, Chen S . Ganoderma tsugae Induces S Phase Arrest and Apoptosis in Doxorubicin-Resistant Lung Adenocarcinoma H23/0.3 Cells via Modulation of the PI3K/Akt Signaling Pathway. Evid Based Complement Alternat Med. 2012; 2012:371286. PMC: 3389685. DOI: 10.1155/2012/371286. View

12.

Montgomery R, Mostaghel E, Vessella R, Hess D, Kalhorn T, Higano C . Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008; 68(11):4447-54. PMC: 2536685. DOI: 10.1158/0008-5472.CAN-08-0249. View

13.

Elledge S . Cell cycle checkpoints: preventing an identity crisis. Science. 1996; 274(5293):1664-72. DOI: 10.1126/science.274.5293.1664. View

14.

Kuo H, Hsu S, Ou C, Li J, Tseng H, Chuang T . Ganoderma tsugae Extract Inhibits Growth of HER2-Overexpressing Cancer Cells via Modulation of HER2/PI3K/Akt Signaling Pathway. Evid Based Complement Alternat Med. 2013; 2013:219472. PMC: 3638576. DOI: 10.1155/2013/219472. View

15.

Tsao C, Cutting E, Martin J, Oh W . The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Urol. 2014; 6(3):97-104. PMC: 4003844. DOI: 10.1177/1756287214528557. View

16.

Boutros R, Lobjois V, Ducommun B . CDC25 phosphatases in cancer cells: key players? Good targets?. Nat Rev Cancer. 2007; 7(7):495-507. DOI: 10.1038/nrc2169. View

17.

Grana X, Reddy E . Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995; 11(2):211-9. View

18.

Mohler J . Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol. 2008; 617:223-34. DOI: 10.1007/978-0-387-69080-3_21. View

19.

KAIGHN M, Narayan K, Ohnuki Y, Lechner J, Jones L . Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979; 17(1):16-23. View

20.

Rodriguez-Berriguete G, Fraile B, Martinez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M . MAP Kinases and Prostate Cancer. J Signal Transduct. 2011; 2012:169170. PMC: 3199183. DOI: 10.1155/2012/169170. View